A laser hair removal treatment on Fitzpatrick IV skin goes sideways three days after the session. The patient calls reporting dark patches over the treated area — post-inflammatory hyperpigmentation that will take months to resolve and may require topical intervention. The practice chart notes the fluence and pulse duration used, but there is no record of a test spot, no documentation of the patient's Fitzpatrick type, and no observation window between the test and the full treatment.
This scenario plays out in aesthetic clinics that treat laser hair removal as a high-volume, protocol-driven service where the patch test is an afterthought or a checkbox. The test spot is not a formality. It is the practice's single most important tool for calibrating parameters to an individual patient's skin response — and, when documented correctly, it is the clinical record that demonstrates the practice met its standard of care.
This article covers how aesthetic practices should structure a laser hair removal patch-test (test-spot) protocol: who needs one, how to perform it, how long to wait, what to document, and how to handle the patient whose test spot reveals an adverse response.
Why the Patch Test Exists
Laser hair removal works by selective photothermolysis — the laser wavelength is absorbed by melanin in the hair shaft, converting light energy to heat that damages the follicle. The same melanin that makes the treatment effective in the hair also exists in the epidermis, particularly in patients with Fitzpatrick skin types IV through VI. If the epidermal melanin absorbs too much energy, the result is thermal injury: burns, blisters, and post-inflammatory hyperpigmentation (PIH).
A test spot is a controlled, limited-area application of the laser at the planned treatment parameters (or a conservative starting point) to observe how the patient's skin responds before committing to a full treatment area. It answers two questions:
- Are these parameters safe for this patient's skin? — no excessive erythema, no blistering, no immediate pigment change.
- Are these parameters effective? — perifollicular edema and erythema within minutes of treatment indicate follicular injury, the clinical endpoint for hair removal.
The test spot de-risks the full treatment. Without it, the practice is guessing at parameters based on skin-type classification alone, which is an imperfect predictor of individual response.
Who Needs a Patch Test
All patients, with nuance
Best practice is to perform a test spot on every new patient before the first full treatment session. This is the position of the British Medical Laser Association (BMLA) and is standard in evidence-based laser practices.
However, the clinical urgency varies by Fitzpatrick type:
Fitzpatrick I–III. Lower epidermal melanin content means lower risk of competitive absorption and PIH. Many practices in this population treat without a separate test-spot visit, performing a test spot at the beginning of the first session and observing for immediate reaction before proceeding. This is defensible if the practice documents the test spot and its result.
Fitzpatrick IV–VI. Higher epidermal melanin content means higher risk of PIH, burns, and dyspigmentation. A separate test-spot visit with an observation window of 48 hours minimum (and ideally 7–14 days for delayed PIH) is strongly recommended. The American Academy of Dermatology and the American Society for Dermatologic Surgery emphasize that longer wavelengths (Nd:YAG 1064 nm), lower fluences, and longer pulse durations are preferred for these skin types — and that test spots are essential to confirm parameter safety before full treatment.
Any patient with a history of PIH, keloids, recent sun exposure, or recent isotretinoin use. These patients require a test spot regardless of Fitzpatrick type.
When to repeat the patch test
The BMLA advises that a patch test remains valid for approximately 24 months, unless circumstances change:
- The patient has new sun exposure or a tan
- The patient has started or stopped a medication (particularly isotretinoin, photosensitizing agents, or hormonal therapies)
- The practice switches to a different laser device or wavelength
- The laser has been serviced, calibrated, or the handpiece has been changed (serviced devices may deliver energy differently than pre-service parameters)
- The patient's skin condition has changed (new pigmentation, active inflammation, recent chemical peel)
Any of these changes warrants a new test spot, documented with the updated clinical context.
Performing the Test Spot: Step by Step
1. Fitzpatrick classification and intake
Before the test spot, the practice must document the patient's Fitzpatrick skin type. This is not a visual assessment alone — the Fitzpatrick scale classifies skin by its reaction to sun exposure (burning vs. tanning behavior), not by skin color. A patient who appears to have light skin but reports a history of hyperpigmentation after insect bites or minor cuts may be at higher risk for PIH than their skin tone suggests.
Document:
- Fitzpatrick type (I–VI), with the questions asked to determine it
- History of PIH, keloids, or abnormal scarring
- History of herpes simplex in the treatment area (may require antiviral prophylaxis)
- Current medications — including prescription, over-the-counter, and herbal/homeopathic agents. Isotretinoin requires a 6–12 month washout. Photosensitizers (tetracyclines, NSAIDs, St. John's wort, certain ayurvedic preparations containing photosensitizing botanicals) require parameter adjustment. Topical retinoids should be discontinued 1 week before treatment.
- Recent sun exposure or tanning bed use
- History of previous laser or light-based treatments and outcomes
2. Parameter selection
The starting parameters for the test spot should be selected based on:
- Wavelength. For Fitzpatrick I–III, alexandrite (755 nm) or diode (800–810 nm) may be appropriate. For Fitzpatrick IV–VI, Nd:YAG (1064 nm) is the preferred wavelength due to its deeper penetration and lower epidermal melanin absorption, as confirmed in StatPearls (NCBI) laser safety guidelines.
- Fluence (energy density). Start at the lower end of the recommended range for the patient's skin type. Increase only if the test spot shows no adverse reaction but also no clinical endpoint.
- Pulse duration. Longer pulse durations are safer for darker skin because they allow heat to dissipate from the epidermis while still damaging the follicle. This is the principle behind super-long-pulse Nd:YAG protocols for Fitzpatrick V–VI.
- Spot size. Use the same spot size planned for the full treatment.
- Cooling. Contact cooling, cryogen spray, or forced cold air must be used during the test spot, matching the cooling planned for the full treatment. Cooling protects the epidermis and is not optional for Fitzpatrick IV–VI.
3. Test spot application
Select a small area (1–2 cm²) within or adjacent to the planned treatment zone. The area should be representative of the treatment zone's skin type and hair density but in a location where a potential adverse reaction would be least visible if it occurs (e.g., along the jawline rather than the cheek for facial treatments, or medial thigh rather than bikini line for body treatments).
Document the exact location with a photograph or anatomic notation.
Apply 3–5 pulses at the selected parameters. Observe the immediate response:
- Perifollicular erythema and edema. Expected clinical endpoint. Indicates follicular injury. This is the desired reaction.
- Immediate epidermal whitening or graying. Concerning. Suggests epidermal injury. Reduce fluence.
- Blistering. Stop. Reduce fluence significantly and re-test at a later date.
- No visible reaction. May indicate insufficient fluence. Consider increasing for the full treatment, but do so conservatively.
4. The observation window
This is where practices diverge, and where the protocol matters most.
- Minimum observation: 24–48 hours. The BMLA considers 24–72 hours a minimum wait. This captures immediate and near-term reactions — erythema, edema, blistering, and early pigment change.
- Recommended for Fitzpatrick IV–VI: 7–14 days. PIH may not appear for several days to two weeks after treatment. A test spot that looks benign at 48 hours can develop significant hyperpigmentation by day 7. The PMC-published systematic review and network meta-analysis on PIH prevention (Lasers in Surgery and Medicine, 2026) found that PIH incidence typically peaks between weeks 4 and 8, but clinically significant PIH can be visible as early as 1–2 weeks post-treatment.
- What the practice should communicate to the patient: "We've performed a test spot at the settings we plan to use for your treatment. We need to wait [X days] to make sure your skin responds well. During this time, please watch for [darkening, blistering, prolonged redness] and contact us if you notice any of these. We'll call you on [date] to check in."
5. Follow-up evaluation
At the end of the observation window, the practice evaluates the test spot:
- No adverse reaction and clinical endpoints achieved. Proceed with full treatment at the test parameters.
- Mild erythema resolved, no PIH. Proceed. May consider a conservative fluence increase if follicular response was minimal.
- PIH detected. Do not proceed at these parameters. Reduce fluence, increase pulse duration, switch to a longer wavelength, or consider that the patient may not be a candidate for laser hair removal with the available device. Document the finding and the parameter adjustment. Re-test at the revised parameters with a new observation window.
- Blistering or prolonged erythema. Do not proceed. The patient's skin is reacting adversely to the energy level. Significant parameter reduction is required, and a repeat test spot at lower fluence should be performed after the skin has fully healed.
Documentation: The Record That Protects the Practice
The test spot and its outcome must be documented in the patient's treatment record. A well-documented test-spot record includes:
At the test-spot visit
- Date of test spot
- Patient's Fitzpatrick type and how it was determined
- Intake history (medications, sun exposure, prior treatments, PIH history)
- Device used (manufacturer, model, wavelength)
- Parameters: fluence (J/cm²), pulse duration (ms), spot size (mm), cooling method
- Test spot location (anatomic description or photograph)
- Number of pulses applied
- Immediate skin response (erythema, edema, perifollicular reaction, any adverse finding)
- Patient instructions for the observation period
- Scheduled follow-up date
At the follow-up evaluation
- Date of evaluation
- Test spot site appearance: normal, erythema, PIH, blistering, hypopigmentation
- Photograph of the test spot site (same lighting and positioning as the initial photograph)
- Clinical decision: proceed at test parameters, adjust parameters (specify), or defer treatment
- If parameters are adjusted, the revised parameters and rationale
- Plan for full treatment
This documentation is the practice's evidence that it exercised appropriate clinical judgment before performing a procedure that carries known risks. In the event of a patient complaint, board inquiry, or malpractice claim, a complete test-spot record is the single most defensible document the practice can produce.
Special Considerations
IPL for hair removal
IPL (intense pulsed light) is not a laser — it emits a broad spectrum of wavelengths rather than a single coherent beam. IPL is generally not recommended for Fitzpatrick V–VI due to its non-selective energy delivery and high risk of epidermal injury. For Fitzpatrick IV, IPL may be used with extreme caution, conservative parameters, and mandatory test spots with extended observation. The NCBI StatPearls reference on laser Fitzpatrick skin type recommendations explicitly notes that IPL's non-selective approach increases melanin absorption in the skin, leading to higher complication rates in darker skin.
Multiple body areas
Hair density, hair thickness, skin thickness, and melanin content vary across body areas. A test spot on the bikini line does not validate parameters for the upper lip. Best practice is to perform a separate test spot for each distinct body area planned for treatment, particularly when the areas have different Fitzpatrick characteristics (e.g., sun-exposed face vs. covered body areas).
Delayed PIH: the silent complication
The most problematic adverse event in laser hair removal is delayed-onset PIH — hyperpigmentation that appears days to weeks after a treatment that looked completely benign at the time of service. This is why the observation window for Fitzpatrick IV–VI must extend beyond 48 hours.
The 2026 systematic review and network meta-analysis published in Lasers in Surgery and Medicine examined interventions to prevent PIH after laser and energy-based device treatments. Key findings relevant to the patch-test protocol:
- PIH is the most common adverse effect following laser treatments.
- PIH incidence peaks between 4 and 8 weeks post-treatment.
- Among the interventions studied, intradermal tranexamic acid and topical corticosteroids were the most effective at reducing PIH incidence. Whitening agents (including hydroquinone) showed inconsistent results, and sunscreen monotherapy was not effective compared with placebo. One included trial found that starting a topical agent roughly two weeks before laser therapy significantly reduced PIH.
- The review concludes that preventive strategies should be built into laser treatment planning, particularly for patients identified as higher-risk for hyperpigmentation.
For practices serving a diverse patient population, the patch-test protocol should incorporate a discussion of pre-treatment skin preparation for patients identified as high PIH risk during intake — including hydroquinone priming and strict photoprotection — not just the laser parameters themselves.
Building the Practice Protocol
A complete laser hair removal patch-test protocol should be a written document, approved by the medical director and the laser safety officer (if the practice has one — see ANSI Z136.3 requirements), and accessible to all clinical staff. It should specify:
- Who requires a test spot. All new patients, with a separate visit for Fitzpatrick IV–VI.
- Parameter selection framework. Starting fluence, pulse duration, and wavelength by Fitzpatrick type, based on manufacturer recommendations and published clinical guidelines.
- Observation window. Minimum 48 hours for Fitzpatrick I–III; minimum 7–14 days for Fitzpatrick IV–VI.
- Documentation requirements. The elements listed above, recorded at both the test-spot visit and the follow-up evaluation.
- Escalation. What to do when the test spot reveals an adverse reaction — parameter adjustment, re-test, deferral, or referral.
- Pre-treatment preparation. For high-PIH-risk patients, the protocol should specify whether the practice recommends hydroquinone priming, retinoic acid cessation, or other preparatory measures before the test spot.
- Validity period. When the test spot expires and must be repeated (24 months, per BMLA guidance, or sooner if circumstances change).
Sources
- StatPearls (NCBI), "Laser Fitzpatrick Skin Type Recommendations": https://www.ncbi.nlm.nih.gov/books/NBK557626
- PMC, "Interventions to Prevent Postinflammatory Hyperpigmentation After Laser and Energy-Based Device Treatments: A Systematic Review and Network Meta-Analysis" (Lasers in Surgery and Medicine, 2026): https://pmc.ncbi.nlm.nih.gov/articles/PMC12997392
- PMC, "Noninvasive Cosmetic Treatments for Fitzpatrick IV–VI: A Narrative Review of Safety and Efficacy Guidelines" (Plastic and Reconstructive Surgery, 2026): https://pmc.ncbi.nlm.nih.gov/articles/PMC13012588
- British Medical Laser Association (BMLA), "How to make a patch work: Laser treatments and patch tests": https://bmla.co.uk/how-to-make-a-patch-work-laser-treatments-and-patch-tests
- Cleveland Clinic, "Laser Hair Removal: How it Works & What to Expect": https://my.clevelandclinic.org/health/treatments/21757-laser-hair-removal
- PMC, "Standard operating protocol for utilizing energy-based devices in dermatology" (Journal of Cosmetic Dermatology, 2024): https://pmc.ncbi.nlm.nih.gov/articles/PMC11626368
- OSHA, "Laser Hazards — Standards": https://www.osha.gov/laser-hazards/standards
- Laser Institute of America (LIA), "Laser Safety Standards": https://www.lia.org/resources/laser-safety-information/laser-safety-standards
